Trial phase

Phase 3

2 sourced research updates tagged Phase 3, newest first — what changed, what the evidence shows and what it means for how people run a protocol.

GLP-1 & metabolic2026-08-10

Retatrutide's Phase 3 results are in — and the filing slipped to 2027

Eli Lilly reported in July 2026 that retatrutide, a triple GLP-1/GIP/glucagon receptor agonist, met its primary endpoints in the Phase 3 TRIUMPH-2 and TRIUMPH-3 trials, with weight loss of roughly…

Retatrutide Tirzepatide GLP-1 receptor agonist GIP receptor agonist Glucagon receptor agonist Phase 3

GLP-1 & metabolic2026-08-05

When will orforglipron actually be available to fill at a pharmacy?

Orforglipron is a once-daily oral small-molecule GLP-1 receptor agonist that has completed its Phase 3 ATTAIN and ACHIEVE programs and is under regulatory review.

Orforglipron GLP-1 receptor agonist Phase 3

All research updates

Who maintains this page

The DoseRoutine Editorial Team maintains the compound library and the interaction rule set behind DoseRoutine. We summarize published trials, regulatory documents (FDA, EMA) and company announcements into plain-English updates. Every factual claim on a post is tied to a linked source below.

Posts are written and reviewed by the editorial team, not by a licensed clinician. This is educational reference content — it never recommends an amount for you to take.

Cite DoseRoutine

Quoting or summarizing this page? Please credit DoseRoutine and link back.

DoseRoutine — DoseRoutine. https://doseroutine.com/blog/tag/phase/phase-3

Retatrutide's Phase 3 results are in — and the filing slipped to 2027

When will orforglipron actually be available to fill at a pharmacy?

Track this in your own routine